Following U.S. Stocks may claim a “BIG Change,” in the course of current trading session: Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF)
Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF), with shares dwindled - 57.69% is now trading at $2.34, hitting new 52-week low of $2.26. 1,775,745 shares changed hands versus its average volume of 225,855 shares. The stock has price to book ratio of 21.31. With recent decline, the year-to-date (YTD) performance reflected a 58.29% gain below last year. During the past month the stocks gain 18.63%, bringing three-month performance to 49.73% and six-month performance to 72.59%. The mean recommendation of analysts for this stock is 2.00. (where 1=Buy, 5=Sale).
Latest NEWS regarding these Stocks are depicted underneath:
Can-Fite BioPharma Ltd. (NYSEMKT:CANF)
Today, Can-Fite BioPharma Ltd. (CANF), declared that its Phase II/III psoriasis trial for the Corporation’s drug candidate CF101 did not achieve its primary endpoint.
This Phase II/III double-blind, placebo-controlled study was designed to test the efficacy of CF101 in patients with moderate-to-severe plaque psoriasis. Can-Fite enrolled a total of 326 patients through 17 clinical centers in the U.S., Europe, and Israel. The first study segment was comprised of three arms with 103 patients who received either 1 mg of CF101; 2 mg of CF101; or placebo. All patients receiving placebo were switched to either 1 mg or 2 mg of CF101 after 12 weeks and continued receiving treatment until week 24. Following a positive interim analysis, Can-Fite continued to enroll patients to the second segment of the study. The second study segment was comprised of two arms with 223 patients receiving either 2 mg of CF101 or placebo. All patients receiving placebo were switched to 2 mg of CF101 after 16 weeks and continued receiving treatment until week 32. The primary efficacy endpoint was a statistically noteworthy improvement in the Psoriasis Area Sensitivity Index (PASI) score relative to placebo treatment, and the secondary endpoints were, among others, the Physicians’ Global Assessment (PGA) score in addition to various safety parameters.
The proportion of patients treated with CF101 who achieved at least a 75% improvement from baseline in disease severity at week 12, as measured by PASI 75 was 8.5% vs. 6.9% in the placebo group. With respect to PGA, 6.4% of patients treated with CF101 achieved clear or almost clear skin at week 12 contrast to 3.4% of the placebo patients. CF101 was found to be safe and well tolerated.
Can-Fite BioPharma, Ltd., a clinical-stage biotechnology corporation, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
